Close
FINDING CURES TOGETHER<sup>SM</sup>
  • Home
  • Funding Opportunity Detail

AACR-Bayer Innovation and Discovery Grants | Grant Status - Closed

Grant Amount$ 25,000 USD

Grant Term

1 Year(s)

Start of Grant Term

10/1/2017

Application Deadline

7/13/2017 1:00:00 PM

Application Deadline Time Zone

Eastern Standard Time

Decision Date

9/2017

Additional Information

​April 17, 2018 - Grant recipient must attend the Grants Reception and Dinner and formally accept the grant. For the Grantee's registration and attendance at this Annual Meeting, the Grantee will be reimbursed for eligible travel expenses of up to $1,000, which will be separate from the grant.

Description

Bayer and the AACR are proud to announce the 2017 AACR-Bayer Innovation and Discovery Grants.

This grants partnership will promote the key tenets of the Bayer  Grants4Targets™ Initiative, providing new treatment options for cancers with high unmet medical need, encouraging innovation and translation of ideas from basic research into novel drugs, and fostering collaborations between excellent academic groups and the pharmaceutical industry. This program offers one-year grants of $25,000 to meritorious projects that examine important, and druggable*, novel targets and biomarkers.

It is anticipated that 10 grants will be funded.

*For the purposes of this grant program, a "druggable" target is defined as a nucleic acid or a protein (e.g.,  an enzyme, a receptor) whose activity can be modified by a drug. The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in cancer by relevant in vitro or in vivo models. A cancer-related biomarker might be a protein, a nucleic acid, or a metabolite that can be measured in biological fluids, tissue, or isolated cells for the diagnosis, monitoring, prognosis, or stratification of patients.

Research Project Criteria

These grants will support basic, translational, and/or clinical research projects that examine important and druggable* novel targets and/or biomarkers. The proposed research must be focused in area(s) of oncogenetic signaling, immuno-oncology, and/or antibody drugs/thorium conjugates.

*For the purposes of this grant program, a "druggable" target is defined as a nucleic acid or a protein (e.g., an enzyme, a receptor) whose activity can be modified by a drug. The drug can be a small-molecular weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in cancer by relevant in vitro or in vivo models. A cancer-related biomarker might be a protein, a nucleic acid, or a metabolite that can be measured in biological fluids, tissue, or isolated cells for the diagnosis, monitoring, prognosis, or stratification of patients.

Eligibility Criteria

​In order to be eligible for this opportunity, applicants must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent doctoral degree) in a related field and not currently be a candidate for a further doctoral or professional degree.

Applications will be accepted from independent investigators at all levels who are affiliated with an academic, medical, or research institution within North America.

Investigators may submit only one application for an AACR-Bayer Innovation and Discovery Grant but may concurrently apply for other AACR grants.

Employees or subcontractors of a U.S. government entity or for-profit private industry are not eligible. Employees or subcontractors of a U.S. government entity or for‐profit private industry may serve as Collaborators, but no grant funds may be directed towards these individuals.

Members of the Scientific Review Committee are not eligible to apply for an AACR-Bayer Innovation and Discovery Grant.

Applications will be peer-reviewed by a Scientific Review Committee comprised of researchers and physician-scientisits who are well-respected for their own accomplishments in cancer and drug discovery research and are viewed as leaders in the field. The successful applicants will be notified in September 2017.

Citizenship Requirements

There are no citizenship requirements. However, by submitting an application for this grant, an applicant applying from an institution located in a country in which they are not a citizen or a permanent resident assures that the visa status will provide sufficient time to complete the project and grant term at the institution from which they applied.

AACR Membership Requirements

AACR membership is required. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active-level Membership, and be members in good standing, by Monday, July 13, 2017. The application will be applied to 2017 membership dues. Nonmembers can apply for membership using the Official Application for Membership submitted to the AACR office with the required documents or apply online. Lapsed members can renew their membership through their myAACR account.

Application Instructions

​AACR requires applicants to submit a completed application by 1:00 p.m. U.S. Eastern Time on Thursday, July 13, 2017 to grants@aacr.org, under the subject line "2017 AACR-Bayer Innovation and Discovery Grants Application Submission".

In order to submit a complete application, applicants should read through the Program Guidelines and Application Instructions document carefully, then complete the application template provided by the AACR.

2017 AACR-Bayer Innovation and Discovery Program Guidelines and Application Instructions

2017 AACR-Bayer Innovation and Discovery Grant Experimental Plan Template